10X GENOMICS INC-CLASS A (TXG)
US88025U1097 - Common Stock
10X GENOMICS INC-CLASS A
NASDAQ:TXG (12/31/2024, 8:00:02 PM)
Premarket: 14.5 +0.14 (+0.97%)14.36
+0.01 (+0.07%)
Company Profile
10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. The company is headquartered in Pleasanton, California and currently employs 1,259 full-time employees. The company went IPO on 2019-09-12. The firm's integrated solutions include instruments, consumables and software for analyzing biological systems. Its Chromium platform includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Chromium Single Cell Multiome ATAC + Gene Expression, Visium Spatial Gene Expression, and others.
Company Info
10X GENOMICS INC-CLASS A
6230 Stoneridge Mall Road
Pleasanton CALIFORNIA 94588
P: 19254017300
CEO: Serge Saxonov
Employees: 1259
Website: https://www.10xgenomics.com/
TXG News
9 days ago - The Motley FoolCathie Wood Goes Bargain Hunting: 3 Stocks She Just BoughtThe aggressive growth fund investor has slowed her shopper this holiday season, but she still made time to build up some of her existing positions.
10 days ago - 10x Genomics, Inc.U.S. District Court Awards 10x Genomics Permanent Injunction in Patent Infringement Lawsuit Against Bruker Corporation's GeoMx Products/PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today it had secured a permanent injunction in the U.S....
2 months ago - 10x Genomics, Inc.TechBio Startup Cure51 Selects 10x Genomics Visium HD for New Drug Discovery Initiative/PRNewswire/ -- French TechBio startup Cure51 and 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that Cure51...
2 months ago - 10x Genomics, Inc.10x Genomics Reports Third Quarter 2024 Financial Results/PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the third quarter ended...
3 months ago - 10x Genomics, Inc.10x Genomics Delivers 'Single Cell for a Single Cent' with New Chromium Launches/PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today the launch of two new Chromium products intended...
3 months ago - Investor's Business Daily10x Genomics Crashes After 'Disruptive' Reorg Upsets Third-Quarter SalesThe company is undergoing a reorganization that has proven more "disruptive" than previously expected.
TXG Twits
Here you can normally see the latest stock twits on TXG, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
